# **Coronary Dissection – Back to the Future – Finding Good in the Bad!**

Rajkumar Natarajan,<sup>1,2</sup> Natasha Corballis,<sup>1,2</sup> Ioannis Merinopoulos,<sup>1,2</sup> Vassilios S Vassiliou<sup>1,2†</sup> and Simon C Eccleshall<sup>11</sup>

*1. Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK; 2. Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, UK*

*VSV and SCE contributed equally.*

#### *<https://doi.org/10.17925/HI.2024.18.2.5>*

In thas been recognized for decades that dissections occur as a mechanism of balloon angioplasty. A successful angioplasty result contains some degree of intimal splitting and disruption, which usually heals well. Nonethel t has been recognized for decades that dissections occur as a mechanism of balloon angioplasty. A successful angioplasty result contains some degree of intimal splitting and disruption, which usually heals well. Nonetheless, some dissections are extensive, leading to serious ischaemic complications. The concept of therapeutic coronary dissection started evolving in the 1970s and seems to be a favourable the mechanism of balloon angioplasty and the morphological changes in the plaque post-balloon angioplasty. In the early days of balloon angioplasty, there was an enormous interest in dissections, mainly to prevent acute vessel closure events and to address the importance of their occurrence in relation to vessel restenosis. We will review the historical background, studies defining the clinical, angiographic and morphological patterns of the dissection spectrum and various currently evolving management strategies.

#### **Keywords**

Coronary dissections, dissection classification, dissection during drug-coated balloon (DCB) angioplasty, dissections and their management, coronary injury, dissections on OCT

**Disclosures:** Vassilios S Vassiliou has received honoraria for speaking at conferences from Daichii Sankyo and Novartis and has received a research grant from B Braun for investigator-initiated research. Simon C Eccleshall has received research grants for investigatorinitiated research and lecture honoraria from B Braun and acts as a consultant for B Braun, Medtronic, and MedAlliance. Rajkumar Natarajan, Natasha Corballis and Ioannis Merinopoulus have no financial or non-financial relationships or activities to declare in relation to this article.

**Review process:** Double-blind peer review.

**Compliance with ethics:** This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

**Data availability:** Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.

**Authorship:** All named authors meet the criteria of the International Committee of Medical Journal Editors for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.

**Access:** This article is freely accessible at touchCARDIO.com. © Touch Medical Media 2024.

**Received:** 14 October 2024

**Accepted:** 26 November 2024

**Published online:** 18 December 2024

**Citation:** *Heart International.* 2024;18(2):14–23

**Corresponding author:** Dr Rajkumar Natarajan, Department of Cardiology, Norfolk and Norwich University Hospital, Colney Lane, NR4 7UY, Norwich, Norfolk, UK. E: r.natarajan@uea.ac.uk

**Support:** No funding was received in the publication of this article.

Forty-seven years ago, Andreas Gruentzig introduced 'percutaneous transluminal coronary angioplasty' (PTCA) as a new approach to treating symptomatic occlusive coronary artery disease.<sup>[1](#page-8-0)</sup> The mechanism of balloon angioplasty (BA) formed the foundation around which newer equipment and technologies were developed, including plain old balloon angioplasty (POBA), bare-metal stents (BMS), drug-eluting stents (DES) and drug-coated balloons (DCBs), each addressing specific risks of earlier technologies.<sup>2-4</sup> Coronary artery dissection is a frequent result of vessel injury caused by balloon dilatation. Intravascular ultrasound (IVUS) studies have demonstrated its presence in  $50-80\%$  of procedures.<sup>[5,6](#page-8-2)</sup> With the return of BA with DCB technology, dissection is now frequently accepted to achieve a 'DCB-only' approach. Having stents on the shelf, there is room for aggressive yet controlled lesion preparation. However, coronary dissections remain the most common reason for bailout stenting (BOS) in various DCB studies. $7-10$  Moreover, the outdated National Heart, Lung and Blood Institute (NHLBI) angiographic classification is still in use and, notably, has not been validated or updated recently.[11](#page-8-4)

During the POBA era, coronary dissection leading to acute or subacute abrupt closure was the most feared complication.<sup>12</sup> Efforts were made to identify clinical and angiographic predictors to prevent and manage such dissections. The purpose of this article is to review the historical background, studies defining clinical, angiographic and morphological patterns of the dissection spectrum and various currently evolving management strategies.

#### **Pre-stent era 1977–1990**

# Historical background of coronary dissections

#### Coronary dissection: An inherent risk of balloon angioplasty

History was made on 16 September 1977 when Andreas Gruentzig performed the first transluminal balloon catheter inflation of a discrete left anterior descending artery stenosis in a 38-year-old male patient using a modified, non-steerable balloon dilation catheter.<sup>[1](#page-8-0)</sup> When the results of this novel innovation were presented at the American Heart Association meeting in November 1977, they were well received and resulted in wider adoption.<sup>[11](#page-8-4)</sup> In March 1979, the Cardiac Diseases Branch of the NHLBI began centrally accumulating baseline and follow-up data to gain knowledge of the acute and long-term results of PTCA.<sup>11</sup> According to the PTCA Manual of Operations, 'coronary intimal dissection (intimal tear) was defined as the presence of angiographically evident intimal damage producing either an intraluminal filling defect or extraluminal extravasation of contrast material; coronary dissection was considered a complication of PTCA if it caused major luminal obstruction or was associated with coronary occlusion, myocardial infarction (MI) or deterioration of flow necessitating emergency coronary artery bypass graft (CABG)'.[13](#page-8-6)

The 1983 complication report of the NHLBI PTCA registry showed an overall rate of 9.4% intimal tear or coronary dissection in the initial 1977–1981 cohort of 1,500 patients from 73 participating centres, with 31% of these dissections leading to major complications of MI, CABG or death[.13](#page-8-6) With an unpredictable occurrence, coronary dissection was recognized as the leading cause of abrupt vessel closure and became the most common indication for emergency surgery, which also carried high early morbidity and mortality risks.<sup>14-16</sup> With substantial technological advances and more refined tools, the success rates and indications for PTCA expanded exponentially, even in more complex and high-risk patients.<sup>[11](#page-8-4)</sup> Despite improved efficacy, the incidence of complicated dissections remained unchanged in the 1985–1986 NHLBI cohort.[17](#page-8-8) Meanwhile, concerns were also raised that intimal dissections accelerated early restenosis.<sup>18-20</sup>

The credibility of the novel technology was challenged due to the limited means of managing acute vessel complications, high restenosis rates and their associated  $costs<sup>13–17</sup>$  $costs<sup>13–17</sup>$  $costs<sup>13–17</sup>$ . In recognition of the incidence of unavoidable dissections, research efforts continued for many years to study the pathophysiology and clinical and angiographic risk predictors and define the precise relationship between intimal dissection and restenosis.[12,20–22](#page-8-5) Management strategies also evolved from emergency CABG to various repeat angioplasty techniques during early POBA years and subsequently to BOS.

#### Pathomorphology of coronary dissections Coronary dissections under microscopy

BA results in dilatation of the vascular lumen, with the underlying mechanism attributed to the redistribution and compression of atheromatous plaque, as proposed by Dotter and Judkins, and Gruentzig; however, this has never been proven. $23,24$  The exact mechanism remained ill-defined, with various theories being proposed. In 1981, Block et al. described plaque splitting at its thinnest portion in two patients following BA.[25](#page-8-11) In 1983, Waller et al. studied early histological changes occurring from 4 h to 30 days post-BA in several patients.[16](#page-8-12)[26](#page-8-13) The following series of possible mechanisms were reported: intimal tears, cracks or fractures with variable degrees of localized or extensive medial penetrations; intimal–medial dissections propagating either antegrade, retrograde or both directions; and, sometimes, lifting of the plaque from the deep medial layer.<sup>[26](#page-8-13)</sup> Deep extensive medial dissections may result in a propagating intramural haematoma, subsequently occluding the lumen. The extensive intimal–medial dissection plane may lift the plaque from the media, creating a large flap that eventually curls up into the lumen, causing abrupt vessel closure. Similar patterns of intimal or medial splitting, plaque fractures and haemorrhage were described in autopsy studies.[27,28](#page-8-14)

#### Coronary dissections under angiography

The terms 'intimal tears or flaps' and 'dissection' were used freely to describe the spectrum of morphological alterations on angiography[.29–31](#page-8-15) However, in reality, the result may give diverse angiographic findings, often dictated by the lesion characteristics.<sup>[30,32](#page-8-16)</sup> To classify the angiographic appearances following PTCA, Holmes et al. first described four distinct patterns of immediate angiographic changes in 100 patients, namely, smooth-walled dilatation, intimal flaps or intramural split or dissection, intraluminal haziness and no change in the lesion. $29$  However, there was no anatomical correlation.<sup>[29](#page-8-15)</sup> Dorros et al. showed safe healing of intimal dissections following PTCA.<sup>33</sup> Further analysis of the early PTCA registry revealed that about two-thirds of the angiographically detected dissections (9.2%) had a benign course post-PTCA.<sup>[13](#page-8-6)</sup> The NHLBI PTCA registry concluded that angiographic patterns of intraluminal filling defect,

#### <span id="page-1-0"></span>Table 1: NHLBI classification of types of coronary artery dissections during angioplasty



*Types A- F refers to NHLBI classification types of dissections. OCT images in the fifth column depict the counterparts of each NHLBI dissection types and are not the actual OCT runs of the angiogram images shown in column 4. LAD = left anterior descending artery; LAO = left anterior oblique view; NHLBI =* 

*National Heart, Lung and Blood Institute; OCT = optical coherence tomography; PA = posteroanterior; RAO = right anterior oblique view; RCA = right coronary artery.*

linear luminal density or staining and extravasation of contrast with good distal flow are called coronary intimal dissection.<sup>[14](#page-8-7)</sup> When a complicated dissection occurs, it is rapidly observed as well-defined, long intramural contrast channels, large radiolucent spiral tracts with persistence of contrast material, an irregular lumen with contrast hang-up, delayed flow and abrupt closure. Subsequently, Dorros et al. devised the widely used NHLBI angiographic classification of dissections (types A–F) in 1985 based on the cine-loop fluoroscopy images of patients from the PTCA registry.[13](#page-8-6) Clinically, types A and B and stable type C were classified as uncomplicated, whereas type C with suboptimal haemodynamic results and types D and F represent complicated dissection. Type E could be a combination of dissection with thrombus.

This system is useful in providing distinct angiographic categories as shown in *[Table 1](#page-1-0)*, but its application was limited during the late POBA era (*[Figure 1](#page-2-0)*).

#### <span id="page-2-0"></span>Figure 1: Mechanism of balloon angioplasty



#### Angiographic–morphological correlations

The correlation between angiographic appearances and the morphological patterns of BA mechanisms was well described by Bruce F Waller in 1988. $^{21}$  $^{21}$  $^{21}$  He examined histopathological specimens from 76 coronary artery segments containing angioplasty sites from 66 patients with necropsy who died within 30 days of PTCA, comparing the angiographic description by different PTCA operators with the anatomical findings. Interestingly, angiographic 'intimal flaps' (43%) and 'intraluminal haziness' (38%) mostly correlated with intimal–medial splits or cracks of varying degrees, accompanied by localized medial dissection. Four extensive medial dissections (9%) were seen in the intimal flap category, while the haziness pattern had a mix of pure intimal injuries (31%) and laminated thrombus coating (3%). At a 'coronary artery dissection' site, a deep intimal–medial tear (*[Figure 2](#page-2-1)*) with an extensive longitudinal medial dissection had occurred. The adventitial extension was seen in two patients, where the 'extravasated contrast' material correlated to confined coronary perforation (confined rupture). In his later works, there was evidence of regression of these intimal flaps, with no histological signs of previous vessel injury.<sup>[30](#page-8-16)</sup>

## A morphologic–angiographic–clinical nomenclature of dissections

Histopathological studies added to the existing angiographic terms by providing an anatomical perspective. Histologically, dissection was defined as penetration into the medial layer. Angiographic coronary artery dissection describes a visible intimal flap (anatomically equivalent to intimal–medial tear), with contrast staining extending beyond the confines of the angioplasty lesion, with or without clinical symptoms or signs of ischaemia.<sup>[30](#page-8-16)</sup> Such intimal flaps could either extend circumferentially in the short-axis view or propagate in anterograde or retrograde directions longitudinally in the long-axis plane, as shown in *[Figure 3](#page-3-0)*. By using different angiographic projections, an estimate of the biplanar extent is possible. Theoretically, a dissection involving >50% of short-axis circumference or >1 cm of anterograde or retrograde of long-axis length was defined as a complication of angioplasty, whereas anything below these cut-offs were mechanisms. On the contrary, intimal

dissection or split described an intimal flap with contrast staining with no evidence of ischaemia.<sup>[30,31](#page-8-16)</sup>

# Therapeutic dissections: Uncomplicated and safe-to-leave category

During the early years of angioplasty, concerns were raised that intimal tears or dissections accelerate early restenosis.<sup>18-20</sup> To address this, in 1985, Leimgruger et al. studied the haemodynamic significance of uncomplicated angiographic coronary intimal dissections by measuring transtenotic pressure gradient following successful PTCA and examining their relationship with restenosis by using a validated digital electronic caliper method to measure diameter stenosis (DS) severity.<sup>22,34</sup> A transtenotic pressure gradient was obtained using a guide catheter, guidewire and a balloon catheter. By positioning the guidewire and balloon catheter across the coronary stenosis, a pressure port distal to the balloon segment recorded the distal arterial pressure, while the guiding catheter tip at the ostium monitored the proximal arterial pressure. The difference between these phasic pressures yielded the transtenotic pressure gradient using a specialized computer program. Using this technology, the authors demonstrated that such dissections did not increase the risk of restenosis and had a beneficial effect of lowering the restenosis rate if the final transtenotic pressure was ≤15 mm Hg. In fact, if the final gradient was >15 mm Hg, the rate of restenosis was not significantly different between the groups with and without intimal dissections (35 versus 39%; p=non-significant). Matthews et al. then showed that patients with dissections during PTCA are unlikely to develop restenosis at 1-year follow-up.<sup>[35](#page-8-20)</sup> In this observational study of 273 patients, 82% of the dissection group did not develop restenosis. Similar retrospective studies during the same year showed a similar relationship between intimal dissection and restenosis[.35–40](#page-8-20) The term 'therapeutic dissection' was widely used to describe uncomplicated coronary intimal dissections that resulted in an increased cross-sectional area (CSA) and were less likely to develop restenosis.[40,41](#page-8-21) *[Table 2](#page-3-1)* summarizes studies examining the relationship between lesions with or without dissections and restenosis.<sup>22,32,35,42-45</sup>



#### <span id="page-2-1"></span>Figure 2: Diagram showing morphological correlates of angiographic appearances of intraluminal flaps and haziness



# <span id="page-3-0"></span>Figure 3: Morphological correlation of angiographic appearances of complicated coronary arterial dissection

*Diagram showing morphological correlation of angiographic appearances of complicated coronary arterial dissection, caused by deep extensive medial dissection creating a false lumen and compressing the true lumen*

# <span id="page-3-1"></span>Table 2: Summary of studies that examined the relationship between lesions with or without dissections and restenosis<sup>22,32,35,42-45</sup>



*ϕ = uncomplicated dissections; Angiogram f/u = per cent of patients with angiographic follow-up; f/u = follow-up; gradient = final transtenotic pressure gradient in mm Hg; NS = not significant.*

# Complicated dissections: Indeterminate category and 'need-to-graft' category

As described earlier, complications occur when an intimal–medial tear produces a flap that could fold or become free in the lumen, collapsing on itself and causing intussusception, which compromises the lumen.<sup>21</sup> Tissue disruption may produce turbulence (shear stress), stasis and thrombosis, leading to suboptimal haemodynamic results.<sup>46,47</sup> If intervened promptly in suitable cases, the flaps can be made to adhere to the vessel wall through further dilatation techniques, thereby restoring distal flow.[48](#page-8-28) If the flow is compromised despite rescue strategies, the earliest mode of definitive therapy is emergency surgery, as explained below.

In essence, the challenge lies in interpreting dissections via angiography. When intimal damage exposes the thrombogenic plaque layers, contrast fills these furrows during further injections. Angiography reveals hazy or ill-defined margins of an enlarged lumen, with inhomogeneous opacification, double-line or contrast filling defects. Regardless of the mechanism, not all the dissections are visible, and not all visible dissections are complicated. Sometimes, a combination of angiographically undetectable dissection, recoil, refractory spasm and intracoronary thrombus can occur. This is a conundrum still faced today, where an indeterminate angiographic appearance must be classified as either safe or unsafe. Hence, safe dissections may be viewed as a therapeutic mechanism of BA, while unsafe dissections represent a complication of dilatation.

# **Existing classification systems** NHLBI angiographic classification of dissections-1985

Types A–F, as shown in *[Table 1](#page-1-0)*, represent angiographic appearances of the contrast in relation to their clearance and their effect on distal flow, as described in 1985.<sup>49</sup> Neither the circumference nor the length was factored in. It was only in 1991 that Huber et al. retrospectively predicted the clinical outcomes of dissections using NHLBI classification.<sup>39</sup> Of 691 dissections, 543 were type B, which had no higher risk of morbidity and mortality compared with patients with no dissections. A small subgroup of types C–F (n=148) had a statistically significant increase in in-hospital complications against type B. The results are severely limited by the low power of the subgroup and unreported inter- and intraobserver variability. In contrast, slightly better clinical outcomes were observed for

types B–F dissections in an unblinded MERCATOR (Multicentre European Research trial with Cilazapril After angioplasty to prevent Transluminal coronary Obstruction and Restenosis) trial by Hermans et al. in 1992.<sup>40</sup> As shown in *[Table 3](#page-4-0)*, there is no significant difference in long-term events between the different NHLBI types of dissections.<sup>39,40,50</sup> While it is difficult to draw any strong conclusion from these studies with conflicting results, the concept of therapeutic dissections (roughly types A–C, some type Es if the thrombus clears) has been strengthened. Nevertheless, the decision to treat a dissection depends on the clinical and haemodynamic parameters in relation to distal perfusion, and this approach still applies in current practice.

In 2001, Albertal et al. showed that moderate dissections (as classified in *[Table 4](#page-5-0)*), when left unstented, had good outcome with a classification based on clinical relevance.<sup>[50](#page-8-31)</sup>

Various forms of classification of dissections have been reported in studies throughout the years of POBA and the early stent era, mainly based on the operator's experience and preference. While some used mild, moderate and severe dissections, few preferred intimal and coronary arterial dissections.<sup>32</sup> Given the limitations of the NHLBI angiographic classification, newer classification systems using IVUS or angioscopy modalities were proposed to correlate plaque characteristics with dissection risk.<sup>51-53</sup>

# Intravascular ultrasound patterns of dissections

During the stent era, IVUS was increasingly used to show real-time cross-sectional observation of the vessel response to BA and stenting. IVUS gave an in-depth assessment of lesion morphology, and the results of BA with IVUS imaging were consistent with Waller's histopathological studies.<sup>[5](#page-8-2)</sup> This helped in deciding the interventional strategies in the event of suboptimal dilatation according to the plaque composition, calcification and eccentricity. In 1992, Honye et al. and Gerber et al. simultaneously published their IVUS experiences with dissections, suggesting a similar classification system.[5,51](#page-8-2) Honye's classification method failed to have good correlation with angiography detected dissections, as 10 out of 23 angiographic dissections in his study were not seen on ultrasound. On the other hand, Gerber's dissection patterns were very detailed but proved complicated and time-consuming for operators with basic IVUS interpretation skills. The application of this technology declined in



# <span id="page-4-0"></span>Table 3: Summary of studies that examined the relationship between lesions with dissections, NHLBI types and their outcomes<sup>39,40,50</sup>

*Acute complications included abrupt closure, Q wave myocardial infarction and emergency and elective coronary artery bypass. Late events included revascularization. NHLBI = National Heart, Lung and Blood Institute; NR = not reported; TLR = target lesion revascularization.*

### <span id="page-5-0"></span>Table 4: Evaluation of dissections by Albertal et al. based on clinical parameters<sup>[50](#page-8-31)</sup>



the field of dissections due to a number of reasons. First, IVUS failed to detect dissection flaps that adhered to the wall when it transversed beyond them.[54](#page-8-33) Second, it poorly differentiated the echo-free space of thin diseased media from dissection planes. Finally, IVUS-detected severity of dissections did not correlate with any pre-interventional lesion characteristics.[54](#page-8-33) *[Figure 4](#page-5-1)* illustrates IVUS appearances of coronary dissections during percutaneous coronary intervention (PCI).

# Intravascular ultrasound validation of therapeutic dissection concept

However, IVUS technology continued to improve with high-resolution and low-profile catheters. In 2000, Schroeder et al. demonstrated that IVUS-detected therapeutic dissections (mild and moderate group) did not impact acute or long-term outcomes, further substantiating the concept of therapeutic dissections.<sup>[52](#page-8-34)</sup> Schroeder's classification method was rather simple and easy to use, as in *[Table 5](#page-5-2)*.

Following this study, in 2001, Shigeyama et al. attempted to classify the therapeutic dissections category based on angiography into types A–E in relation to the depth and breadth of dissection and the presence of intimal flap or spiral appearance. $53$  However, its clinical application is limited, as the interest was more in the management of indeterminant groups of dissections.

# Optical coherence tomography: A better lens for drug-coated balloon-related dissections?

Since 1991, the use of optical coherence tomography (OCT) has expanded rapidly and is now a preferred modality for precisely imaging coronary luminal architecture, differentiating plaque rupture or erosion, vulnerable plaque identification and dissections.<sup>[55](#page-8-36)</sup> OCT has been considered safe

# <span id="page-5-2"></span>Table 5: Schroeder's intravascular ultrasound dissection criteria<sup>[52](#page-8-34)</sup>



for imaging spontaneous coronary artery dissections, although some clinical risk has been reported. $56-62$  The superior spatial resolution of OCT identifies intramural haematoma, endothelial tears or entry sites of dissection.<sup>55,63</sup> Given the low clinical risk, OCT remains indicated in cases of dissection with diagnostic uncertainty[.57,59,60](#page-8-38) An OCT-guided DCB strategy is an area of interest in recent DCB studies, with reconstruction software allowing accurate quantification of dissection depth and volume, as shown in *[Figure 5](#page-6-0)*. [64–66](#page-9-0) A recent study called TRANSFORM (TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon; ClinicalTrials.gov identifier: NCT03913832) demonstrated that OCT-derived absolute dissection volume had a favourable effect on lumen gain post-DCB in the paclitaxel DCB arm compared with sirolimus arm in small de novo coronary vessels.<sup>64</sup> Furthermore, OCT fused with angiography provides a realistic reconstruction of lumen architecture with vessel wall dissections, guiding operators to formulate a specialized treatment for patient subsets with DCB-related dissections.<sup>[67](#page-9-1)</sup> This could be the future of DCB technology, with further research in this field currently underway.

# **Coronary dissections and risk factors**

Angiographic predictors of dissection risk and its sequelae play a vital role in devising management strategies. In this article, we review the studies identifying clinical and angiographic risk factors, with *[Table 6](#page-6-1)* illustrating such associations.[12,13,17,22,32,40,68–71](#page-8-5)

In NHLBI cohorts, intimal dissections were associated with female gender, right coronary artery lesions, multivessel disease, and eccentric and diffuse disease.<sup>17</sup> In 1986, Ischinger et al. identified complicated angiographic characteristics – such as irregular borders, intraluminal lucency and stenosis located at a bifurcation or a curve – as predictors of dissections.[12](#page-8-5) In 1985, Bredlau et al. showed that the strongest predictor of a major ischaemic complication was the procedural appearance of an intimal dissection, with a 6.5-fold increase in risk of

<span id="page-5-1"></span>Figure 4: Intravascular ultrasound images of coronary dissections during percutaneous coronary intervention



*(a) Echogenic intramural haematoma (d) seen in the dissection plane. (b) Chromoflo IVUS image showing an echo-free space representing a false lumen. (c) A large false lumen compromising the true lumen during PCI as a result of guide-induced dissection and IVUS confirms that the wire is in the false lumen a = adventitia; d = dissection; FL = false lumen; i = intima; IVUS = intravascular ultrasound; m = media; PCI = percutaneous coronary intervention; TL = true lumen*



#### <span id="page-6-0"></span>Figure 5: Measurement of dissection area by optical coherence tomography (QCU-CMS)<sup>[64](#page-9-0)</sup>

*A straight line connecting the edges of the flap of dissection isolates the dissection space from the lumen. The volume of the dissection is calculated by Simpson's rule over the entire length of the dissection*

*QCU-CMS = Quantitative Coronary Ultrasound-Clinical Measurement Solution*

#### <span id="page-6-1"></span>Table 6: Factors associated with coronary dissection[s12,13,17,22,32,40,68–71](#page-8-5)



*\*Intraluminal lucency is a correlate of plaque rupture, ulceration, subintimal haemorrhage or superimposed or recanalized thrombus. RCA = right coronary artery.*

MI, emergency CABG and death.<sup>[72](#page-9-2)</sup> Later, in a haemodynamic study in 1987, Redd et al. first graded the degree of disruption angiographically into intimal (when the luminal or extraluminal contrast staining remained within the confines of the original PTCA lesion) and arterial dissections (when extending beyond the lesion either proximally or distally).<sup>73</sup> The authors studied the relationship between the dynamic behaviour of the transtenotic pressure gradient after each balloon inflations and the presence of disruptions with subsequent vessel closure. Patients with a rising trend in transtenotic pressure gradient had a higher incidence of arterial dissections (25 versus 7%; odds ratio [OR] 4.8; p=0.001) but not the isolated intimal tears alone.<sup>73</sup> Multivariate analysis of procedural variables showed that a rising transtenotic gradient trend (OR 1.99; p=0.002), lesion length (OR 1.11; p=0.007) and post-PTCA gradient (OR 1.06; p=0.001) were strong predictors of arterial dissections. The rising trend in transtenotic pressure was significantly associated with other ischaemic complications, such as acute closure (OR 2.04; p<0.001), CABG (OR 1.13; p<0.001) and MI (OR 2.91; p<0.001). Additionally, in 1989, Black et al. analysed the morphological variables, dissection length, DS of ≥25% following dilatation and video-densitometry assessment of luminal CSA of <2 mm² and were strong correlates of arterial dissection with ischaemic complications.<sup>32</sup> The extraluminal contrast cap had a slightly weak correlation compared with the rest of the variables.

There was mounting evidence that intimal dissections were therapeutic. PTCA operators became more aware of the safety of uncomplicated intimal dissections, and as their experience expanded, the interest in salvaging the indeterminant and complicated dissection group led to a strategy of lesion-specific device therapy to avoid abrupt vessel closure and emergency surgery.

### **Management of coronary dissections: Early and late plain old balloon angioplasty era**

In the early era of POBA, any dissections causing acute coronary occlusion were treated surgically. Despite prompt surgical revascularization, more than 50% of patients developed significant MI due to the unavoidable delay of sternotomy. Notably, vein grafts, rather than the left internal mammary artery (LIMA), were used for expediency.<sup>[74](#page-9-6)</sup> Subsequently in an effort to reverse abrupt vessel closure non-surgically, attempts were made to reopen the occluded vessel by relieving spasm and thrombus pharmacologically, using intracoronary vasodilators, thrombolytics and heparin infusions.<sup>[75,76](#page-9-7)</sup> When these measures were exhausted and MI was imminent, intra-aortic balloon pumps were used to limit myocardial injury before vein grafting.<sup>[76](#page-9-8)</sup> Reperfusion catheters were used in 1986 to allow optimal bypass grafting.<sup>[77,78](#page-9-9)</sup> However, in the absence of chest pain and acute electrocardiogram changes, even large, flow-limiting dissections were treated with semi-elective bypass surgery. A variety of PCI management options were also subsequently devised to deal with unsafe dissections.

# Repeat percutaneous transluminal coronary angioplasty redilatation technique

Immediate repeat dilatation and successful reopening of the occluded dissection in seven patients was first reported in 1984 by Marquis et al.<sup>[79](#page-9-10)</sup> This approach became routine for treating dissections complicating abrupt reclosures during or after PTCA in following years. About 50% of patients had successful restoration of antegrade flow, thereby avoiding extensive myocardial damage and emergency surgery.<sup>12,80,81</sup>

#### Tack-back technique

Further technical improvization was made by using a standard balloon of the same or slightly larger diameter and performing low-pressure inflations at increments of one or two atmospheres for 60–180 s repeatedly to gain patency.<sup>48,68,81,82</sup> In theory, this remodelled the lesion by 'tacking up' the dissected flap and stabilizing dissections with high success rates.<sup>83</sup> The successful tack-back phenomenon restores a patent lumen possibly by allowing the tissue flaps to adhere to the damaged vessel wall. In an analysis of 109 patients, Lincoff et al. demonstrated that prolonged balloon inflation was an independent correlate of successful resolution of vessel closures (OR 5.11; p=0.001) on multivariate analysis.<sup>83</sup>

#### Prolonged balloon inflation using auto-perfusion catheters

When repeat BA failed, prolonged balloon inflations were undertaken with the aid of an auto-perfusion catheter.<sup>[84](#page-9-12)</sup> A specialized large profile Stack haemoperfusion catheter was first used in 1988, maintaining distal vessel perfusion through the proximal and distal catheter holes, simultaneously facilitating prolonged inflations.<sup>85</sup> The inflation durations were 3–30 min depending on the tolerance of the patient. It proved very effective in improving outcomes in PTCA refractory dissections, but its use was limited due to passive inadequate perfusion, unfavourable coronary anatomy (side branch occlusion, small vessel and tortuosity), poor guidewire access to the distal vessel, difficult delivery and the advent of better techniques.<sup>86–90</sup> The Ringer perfusion balloon catheter (Ringer PTCA) is a rapid-exchange 0.014″ compatible balloon catheter that conforms into a helical cylinder upon inflation and maintains distal perfusion flow, as shown in.<sup>91</sup> A prospective, multicentre, single-arm clinical study of 60 patients demonstrated that the balloon was well tolerated in the majority of patients susceptible to procedural ischaemia when inflated for 60 s or more.<sup>92</sup> The Food and Drug Administration recently approved its use in the USA, and it is mainly indicated in PTCA and

bypass grafts.<sup>[93,94](#page-9-17)</sup> This technology could potentially be used in scenarios involving indeterminate dissections that necessitate modification.

# Controlled inflation technique

Progressive coronary dilation, which involves predilating the stenosis with a smaller balloon followed by maximal dilation with an optimally sized balloon, produces less uncontrolled injury and, thus, reduces the incidence of major complications. This was demonstrated by Banka et al. in a study consisting of  $1,486$  vessels.<sup>95</sup> The success rate with this technique was 98.7% in 1,248 partially occluded vessels and 88% in 353 totally occluded vessels. This technique markedly lowered the incidence of acute closure, major dissection, emergency coronary bypass and death in that dilation of both simple and complex lesions.<sup>[95](#page-9-18)</sup>

# Directional coronary atherectomy and balloon pyroplasty

Resection of occlusive dissection flaps causing luminal compromise using Atherocath devices (Devices for Vascular Intervention [DVI], Redwood City, CA, USA) was reported in a few cases with success rates of around 80% during the early 1990s.<sup>96-99</sup> Directional coronary atherectomy did not gain much popularity due to the greater risks of vessel perforation, inconsistent results and technical difficulties. Sealing of dissection flaps by imparting various forms of thermal energies, such as laser, radiofrequency and microwave, had been used in the past around 1990s but remained academic due to the risks of restenosis and cost[.100–104](#page-9-20)

### Bailout stenting

In 1987, intracoronary stainless-steel stents were described to address abrupt closure, and in subsequent years, they were shown to reduce restenosis.<sup>[2](#page-8-1)</sup> Sigwart et al. demonstrated the first emergency implantation of the endoluminal Wallstent (Schneider, Inc, Minneapolis, MN, USA) for acute occlusion caused by dissection in 13 patients in 1988.<sup>105</sup> Stents were effective in achieving better angiographic appearances of intimal dissections by securing the flaps and increasing residual lumen diameter.[106](#page-9-22) Gianturco-Rubin Palmaz-Schatz stents, along with other varieties of BMS, became very popular in handling bailout situations and reducing the incidence of Q-wave MI and emergency CABG.<sup>[83,107,108](#page-9-11)</sup> However, a multitude of thrombotic, bleeding and restenosis risks then ensued with acute and subacute stent thrombosis emerging as a problem.<sup>109-111</sup> When compared with auto-perfusion BA for acute closure in a non-randomized trial, the stent group had a higher subacute reclosure rate and more deaths.<sup>112,113</sup> Emergency CABG was still required when large dissections could not be repaired, the bailout methods failed or perforation occurred, and in the emergency settings, the conduit choice slowly shifted to left internal artery grafts from saphenous veins.<sup>[74,114](#page-9-6)</sup>

Subsequently, stent technology underwent many technical advancements from using heparin-coated thick bare-mounted rigid coils to the ultrathin DESs used currently, yet there are persistent risks of restenosis, thrombosis and stent failures.<sup>115,116</sup>

#### **Drug-coated balloon era**

The concept of DCB angioplasty is 'device-mediated drug delivery' to a target lesion using a conventional semi-compliant balloon coated with an antiproliferative drug.<sup>[4](#page-8-39)</sup> Prior to DCB delivery, the target lesion must be adequately prepared to achieve an acceptable acute lumen gain and to identify lesions prone to acute vessel closure and dissection.<sup>[117](#page-9-26)</sup> In the event of flow-limiting, vessel-threatening dissections and >30% residual stenosis after extensive and optimal lesion preparation, BOS is recommended.<sup>8</sup> The rates of BOS across major DCB studies are around 5–22%, and high-grade coronary dissection remains the predominant

indication for BOS, alongside acute vessel recoil.<sup>7,8,118-122</sup> While the DCB expert consensus document recommends BOS for any dissections equivalent to or greater than type C in the NHLBI angiographic classification, there are studies that have shown that non-flow-limiting moderate dissections, including type C, are safe when left alone.<sup>[8,50,123](#page-8-40)</sup>

Severe dissections (types D and F NHLBI) are universally treated as a complication that requires stent deployment to prevent periprocedural MI. The management of mild-to-moderate dissections (types A–C) generally varies among interventionalists, based on their experience in DCB angioplasty. In the past two decades of the DES era, the vast majority of lesions undergoing PCI are stented.

However, the threshold to consider BOS in cases of dissections will become higher with increasing experience in DCB angioplasty when a refined lesion preparation algorithm is applied.

## **Conclusion**

Coronary dissections are a stumbling block to the widespread adoption of 'DCB-only' angioplasty, and this limitation can be overcome with the lessons from the POBA era and a change in outlook towards conservative management of coronary dissections dictated by the clinical situation and patient safety. Re-learning the avoidance, recognition and management of coronary dissections will facilitate an increased uptake in this promising new PCI concept of 'leave nothing behind'.  $\square$ 

- <span id="page-8-0"></span>1. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet*. 1978;311:263. DOI: 10.1016/S0140-6736(78)90500-7.
- <span id="page-8-1"></span>2. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med*. 1987;316:701–6. DOI: 10.1056/ NEJM198703193161201.
- 3. Nicolas J, Pivato CA, Chiarito M, et al. Evolution of drug-eluting coronary stents: A back-and-forth journey from the bench to bedside. *Cardiovasc Res*. 2023;119:631–46. DOI: 10.1093/cvr/ cvac105.
- <span id="page-8-39"></span>4. Alfonso F. Scheller B. State of the art: Balloon cathe technologies – Drug-coated balloon. *EuroIntervention*. 2017;13:680–95. DOI: 10.4244/EIJ-D-17-00494.
- <span id="page-8-2"></span>5. Honye J, Mahon DJ, Jain A, et al. Morphological effects of coronary balloon angioplasty in vivo assessed by intravascular ultrasound imaging. *Circulation*. 1992;85:1012–25. DOI: 10.1161/01.cir.85.3.1012.
- 6. Davidson CJ, Sheikh KH, Kisslo KB, et al. Intracoronary ultrasound evaluation of interventional technologies. *Am J*
- <span id="page-8-3"></span>*Cardiol*. 1991;68:1305–9. DOI: 10.1016/0002-9149(91)90236-e. 7. Jeger RV, Farah A, Ohlow M-A, et al. Drug-coated balloons for SMALL coronary artery disease (BASKET-SMALL 2): An open-label randomised non-inferiority trial. *Lancet*.
- <span id="page-8-40"></span>2018;392:849–56. DOI: 10.1016/S0140-6736(18)31719-7. 8. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: Third report of the international DCB consensus group. *JACC Cardiovasc Interv*. 2020;13:1391–402. DOI: 10.1016/j.jcin.2020.02.043.
- 9. Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease. *J Am Coll Cardiol*.
- 2020;75:1061–73. DOI: 10.1016/j.jacc.2019.12.046. 10. Khattak S, Liu B, Ishaq M, et al. 52 Incidence and outcomes of bailout stenting following use of sirolimus drug coated balloon. *Heart*. 2020;106(Suppl.2):A41. DOI: 10.1136/heartjnl-2020-BCS.52.
- <span id="page-8-4"></span>11. Mullin SM, Passamani ER, Mock MB. Historical background of the National Heart, Lung, and Blood Institute registry for percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1984;53:3C–6C. DOI: 10.1016/0002-9149(84)90736-7.
- <span id="page-8-5"></span>12. Ischinger T, Gruentzig AR, Meier B, Galan K. Coronary dissection and total coronary occlusion associated with percutaneous transluminal coronary angioplasty: Significance of initial angiographic morphology of coronary stenoses. *Circulation*. 1986;74:1371–8. DOI: 10.1161/01.cir.74. 6.1371.
- <span id="page-8-6"></span>13. Dorros G, Cowley MJ, Simpson J, et al. Percutaneous transluminal coronary angioplasty: Report of complications from the National Heart, Lung, and Blood Institute PTCA registry. *Circulation*. 1983;67:723–30. DOI: 10.1161/01.cir.67.4. 723.
- <span id="page-8-7"></span>14. Cowley MJ, Dorros G, Kelsey SF, et al. Acute coronary events associated with percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1984;53:12C–16C. DOI: 10.1016/0002-9149(84)90738-0.
- 15. Cowley MJ, Dorros G, Kelsey SF, et al. Emergency coronary bypass surgery after coronary angioplasty: The National Heart, Lung, and Blood Institute's percutaneous transluminal coronary angioplasty registry experience. *Am J Cardiol*.
- <span id="page-8-12"></span>1984;53:22C–26C. DOI: 10.1016/0002-9149(84)90740-9. 16. Holmes DR, Vlietstra RE, Mock MB, et al. Follow-up of patients undergoing percutaneous transluminal coronary angioplasty (PTCA): A report from the NHLBI PTCA registry. *Am J Cardiol*. 1982;49:916. DOI: 10.1016/0002-9149(82)92073-2. 17. Holmes DR Jr, Dorros G, Val G, et al. Comparison of
- <span id="page-8-8"></span>complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: The National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. *J Am Coll Cardiol*. 1988;12:1149–55. DOI: 10.1016/0735-1097(88)92593-4. 18. Zarins CK, Lu CT, Gewertz BL, et al. Arterial disruption
- <span id="page-8-9"></span>and remodeling following balloon dilatation. *Surgery*. 1982;92:1086–95.
- 19. Cowley MJ, Vetrovec GW, Wolfgang TC. Efficacy of percutaneous transluminal coronary angioplasty: Technique, patient selection, salutary results, limitations and complications. *Am Heart J*. 1981;101:272–80. DOI: 10.1016/0002-8703(81)90190-3.
- 20. Essed CE, Van den Brand M, Becker AE. Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion

after wall laceration. *Br Heart J*. 1983;49:393–6. DOI: 10.1136/ hrt.49.4.393.

- <span id="page-8-18"></span>21. Waller BF. Morphologic correlates of coronary angiographic patterns at the site of percutaneous transluminal coronary angioplasty. *Clin Cardiol*. 1988;11:817–22. DOI: 10.1002/ clc.4960111204.
- <span id="page-8-19"></span>22. Leimgruber PP, Roubin GS, Anderson HV, et al. Influence of intimal dissection on restenosis after successful coronary angioplasty. *Circulation*. 1985;72:530–5. DOI: 10.1161/01. CIR.72.3.530.
- <span id="page-8-10"></span>23. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. *Circulation*. 1964;30:654–70. DOI: 10.1161/01.CIR.30.5.654.
- 24. Grüntzig A. Die Perkutane Transluminale Dilatation Chronischer Koronarstenosen. Schlegel B, (ed). J.F. Bergmann-Verlag,
- <span id="page-8-11"></span>1979: 874–5. DOI: 10.1007/978-3-642-85454-5\_200. 25. Block PC, Myler RK, Stertzer S, Fallon JT. Morphology after transluminal angioplasty in human beings. *N Engl J Med*. 1981;305:382–5. DOI: 10.1056/NEJM198108133050706.
- <span id="page-8-13"></span>26. Waller BF. "Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters" – The future treatment of atherosclerotic coronary artery disease? A clinical-morphologic assessment. *J Am Coll Cardiol*. 1989;13:969–87.
- <span id="page-8-14"></span>DOI: 10.1016/0735-1097(89)90248-9. 27. Mizuno K, Kurita A, Imazeki N. Pathological findings after percutaneous transluminal coronary angioplasty. *Heart*. 1984;52:588–90. DOI: 10.1136/hrt.52.5.588.
- 28. Soward AL, Essed CE, Serruys PW. Coronary arterial findings after accidental death immediately after successful percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1985;56:794–5. DOI: 10.1016/0002-9149(85)91141-5.
- <span id="page-8-15"></span>29. Holmes DR, Vlietstra RE, Mock MB, et al. Angiographic changes produced by percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1983;51:676–83. DOI: 10.1016/ S0002-9149(83)80114-3.
- <span id="page-8-16"></span>30. Waller BF, Orr CM, Tassel J, et al. Histologic basis of vessel remodeling after various interventional procedures: A comparison of acute (cracks, breaks, tears, stretching) and chronic (tissue proliferation, recoil) changes. In: Lafont A,<br>Topol EJ, (eds). *Arterial Remodelinq: A Critical Factor in Restenosis.* Springer US. Vol. 1997. ;81–110. DOI: 10.1007/978-1-4615-6079- ,<br>1 6
- 31. Waller BF, Orr CM, Pinkerton CA, et al. Coronary balloon angioplasty dissections: "The good, the bad and the ugly". *J Am Coll Cardiol*. 1992;20:701–6. DOI: 10.1016/0735- 1097(92)90027-k.
- <span id="page-8-22"></span>32. Black AJ, Namay DL, Niederman AL, et al. Tear or dissection after coronary angioplasty. Morphologic correlates of an ischemic complication. *Circulation*. 1989;79:1035–42. DOI: 10.1161/01.cir.79.5.1035.
- <span id="page-8-17"></span>33. Dorros G, Spring DA. Healing of coronary artery intimal dissection after percutaneous transluminal angioplasty. *Am J*
- *Cardiol*. 1980;45:423. DOI: 10.1016/0002-9149(80)90802-4. 34. Scoblionko DP, Brown BG, Mitten S, et al. A new digital electronic caliper for measurement of coronary arterial stenosis: Comparison with visual estimates and computerassisted measurements. *Am J Cardiol*. 1984;53:689–93. DOI: 10.1016/0002-9149(84)90387-4.
- <span id="page-8-20"></span>35. Matthews BJ, Ewels CJ, Kent KM. Coronary dissection: A predictor of restenosis? *Am Heart J*. 1988;115:547–54. DOI:
- 10.1016/0002-8703(88)90802-2. 36. Val PG, Bourassa MG, David PR, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: The Montreal Heart Institute experience. *Am J Cardiol*.
- 1987;60:50–5. DOI: 10.1016/0002-9149(87)90485-1. 37. Fleck E, Regitz V, Lehnert A, et al. Restenosis after balloon dilatation of coronary stenosis, multivariate analysis of potential risk factors. *Eur Heart J*. 1988;9 Suppl C:15–8. DOI:
- 10.1093/eurheartj/9.suppl\_c.15. 38. Vandormael MG, Deligonul U, Kern MJ, et al. Multilesion coronary angioplasty: Clinical and angiographic follow-up. *J Am Coll Cardiol*. 1987;10:246–52. DOI: 10.1016/s0735- 1097(87)80003-7.
- <span id="page-8-30"></span>39. Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. *Am J Cardiol*. 1991;68:467–71. DOI: 10.1016/0002-9149(91)90780-o.
- <span id="page-8-21"></span>40. Hermans WR, Rensing BJ, Foley DP, et al. Therapeutic dissection after successful coronary balloon angioplasty: No influence on restenosis or on clinical outcome in 693 patients.

The MERCATOR study group (multicenter European research trial with cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis). *J Am Coll Cardiol*. 1992;20:767–80. DOI: 10.1016/0735-1097(92)90171-i.

- 41. Savage M, Fischman D, Bailey S, et al. 731-4 Vascular remodeling of balloon-induced intimal dissection: Long-term angiographic assessment. *J Am Coll Cardiol*. 1995;25:139A. DOI: 10.1016/0735-1097(95)92031-Y.
- <span id="page-8-23"></span>42. Quigley PJ, Hlatky MA, Hinohara T, et al. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. *Am J Cardiol*. 1989;63:409–13. DOI: 10.1016/0002-
- <span id="page-8-24"></span>9149(89)90309-3. 43. Renkin J, Melin J, Robert A, et al. Detection of restenosis after successful coronary angioplasty: Improved clinical decision making with use of a logistic model combining procedural and follow-up variables. *J Am Coll Cardiol*. 1990;16:1333–40. DOI: 10.1016/0735-1097(90)90373-W.
- <span id="page-8-25"></span>44. Bourassa MG, Lespérance J, Eastwood C, et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol*. 1991;18:368–76. DOI:
- <span id="page-8-26"></span>10.1016/0735-1097(91)90588-z. 45. Hirshfeld JW, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: A multilvariate statistical model to relate lesion and procedure variables to restenosis. *J Am Coll Cardiol*. 1991;18:647–56. DOI: 10.1016/0735-1097(91)90783-6. 46. Landau C, Lange RA, Hillis LD. Percutaneous transluminal
- <span id="page-8-27"></span>coronary angioplasty. *N Engl J Med*. 1994;330:981–93. DOI: 10.1056/NEJM199404073301407.
- 47. Mabin TA, Holmes DR Jr, Smith HC, et al. Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol*. 1985;5:198–202. DOI: 10.1016/s0735-1097(85)80037-1.
- <span id="page-8-28"></span>Sinclair IN, McCabe CH, Sipperly ME, Baim DS. Predictors, therapeutic options and long-term outcome of abrupt reclosure. *Am J Cardiol*. 1988;61:61G–66G. DOI: 10.1016/ s0002-9149(88)80034-1.
- <span id="page-8-29"></span>49. National Heart, Lung, and Blood Institute. Coronary artery angiographic changes after percutaneous transluminal coronary angioplasty. Manual of Operations: NHLBI PTCA Registry. Bethesda, MD: National Heart, Lung, and Blood Institute; 1985:6–9.
- <span id="page-8-31"></span>50. Albertal M, Langenhove G, Regar E, et al. Uncomplicated moderate coronary artery dissections after balloon angioplasty: Good outcome without stenting. *Heart*. 2001;86:193–8. DOI: 10.1136/heart.86.2.193.
- <span id="page-8-32"></span>51. Gerber TC, Erbel R, Görge G, et al. Classification of morphologic effects of percutaneous transluminal coronary angioplasty assessed by intravascular ultrasound. *Am J Cardiol*. 1992;70:1546–54. DOI: 10.1016/0002-9149(92)90455-
- <span id="page-8-34"></span>8. 52. Schroeder S, Baumbach A, Mahrholdt H, et al. The impact of untreated coronary dissections on acute and long-term outcome after intravascular ultrasound guided PTCA. *Eur*
- <span id="page-8-35"></span>*Heart J*. 2000;21:137–45. DOI: 10.1053/euhj.1999.1754. 53. Shigeyama J, Ito S, Kondo H, et al. Angiographic classification of coronary dissections after plain old balloon angioplasty for prediction of regression at follow-up. *Jpn Heart J*.
- <span id="page-8-33"></span>2001;42:393–408. DOI: 10.1536/jhj.42.393. 54. van der Lugt A, Gussenhoven EJ, von Birgelen C, et al. Failure of intravascular ultrasound to predict dissection after balloon angioplasty by using plaque characteristics. *Am Heart J*.
- <span id="page-8-36"></span>1997;134:1075–81. DOI: 10.1016/s0002-8703(97)70028-0. 55. Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the international working group for intravascular optical coherence tomography standardization and validation. *J Am Coll Cardiol*. 2012;59:1058–72. DOI: 10.1016/j. jacc.2011.09.079.
- <span id="page-8-37"></span>56. Alfonso F, Paulo M, Gonzalo N, et al. Diagnosis of spontaneous coronary artery dissection by optical coherence tomography. *J Am Coll Cardiol*. 2012;59:1073–9. DOI: 10.1016/j. jacc.2011.08.082.
- <span id="page-8-38"></span>Barber-Chamoux N, Souteyrand G, Combaret N, et al. Contribution of optical coherence tomography imaging in management of iatrogenic coronary dissection. *Cardiovasc Revasc Med*. 2016;17:138–42. DOI: 10.1016/j. carrev.2016.01.009.
- 58. Barbieri L, D'Errico A, Avallone C, et al. Optical coherence tomography and coronary dissection: Precious tool or useless surplus? *Front Cardiovasc Med*. 2022;9:822998. DOI: 10.3389/ fcvm.2022.822998.
- 59. Chen X, Hu S, Yu B, et al. TCT-377 characteristic and diagnosis of spontaneous coronary artery dissection by optical coherence tomography. *J Am Coll Cardiol*. 2023;82:B151. DOI: 10.1016/j.jacc.2023.09.385.
- 60. Jackson R, Al-Hussaini A, Joseph S, et al. Spontaneous coronary artery dissection: Pathophysiological insights from<br>optical coherence tomography. JACC Cardiovasc Imaging.<br>2019;12:2475–88. DOI: 10.1016/j.jcmg.2019.01.015.<br>61. Vizzi V, Johnson TW, Jenkins N, et al. Dynamic s
- coronary artery medial and adventitial layers with vasospasm: New insights using OCT. *Int J Cardiol*. 2013;167:2344–5. DOI: 10.1016/j.ijcard.2012.11.039.
- 62. Ramalho AR, Silva Marques J, Oliveira Santos M, Matos V. Optical coherence tomography-guided full plastic jacket in spontaneous coronary artery dissection. *JACC Cardiovasc Interv*. 2017;10:413–4. DOI: 10.1016/j.jcin.2016.10.028.
- 63. Bezerra HG, Costa MA, Guagliumi G, et al. Intracoronary optical coherence tomography: A comprehensive review<br>clinical and research applications. *JACC Cardiovasc Interv.*<br>2009;2:1035–46. DOI: 10.1016/j.jcin.2009.06.019.
- <span id="page-9-0"></span>64. Serruys PW, Tobe A, Ninomiya K, et al. Editorial: Is the axiom of balloon angioplasty, "the more you gain the more you lose", still true in the era of DCB with paclitaxel? *Cardiovasc Revasc Med*. 2024;6:S1553-8389(24)00144-1. DOI: 10.1016/j. carrev.2024.04.001.
- 65. Li L, Zhao L, Wang J, et al. Optical coherence tomography-guided drug coated balloon in non-small de novo coronary artery lesions: A prospective clinical research. *Am J Transl Res*. 2021;13:11617–24.
- 66. Yamamoto T, Kawamori H, Toba T, et al. Clinical impact of optical coherence tomography findings after drugcoated balloon treatment for patients with acute coronary syndromes. *Int J Cardiol*. 2023;387:131149. DOI: 10.1016/j. ijcard.2023.131149.
- <span id="page-9-1"></span>67. Poon EKW, Ninomiya K, Kageyama S, et al. Two facets of shear stress post drug coating balloon: Angiography versus optical coherence tomography fusion approach. C*irc Cardiovasc Imaging. 2024;17:e016279. DOI: 10.1161/*<br>CIRCIMAGING.123.016279.<br>68. Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence and
- <span id="page-9-4"></span>consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. *Circulation*. 1990;82:739–50. DOI: 10.1161/01.cir.82.3.739.
- <span id="page-9-5"></span>69. Roubin GS, Gruentzig AR. Percutaneous transluminal coronary angioplasty: State of the art and future directions. *Int J Card*
- *Imaging*. 1985;1:143–54. DOI: 10.1007/BF01884103. 70. Roubin GS, Douglas JS Jr, King SB 3rd, et al. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty. A prospective randomized study. *Circulation*. 1988;78:557–65. DOI: 10.1161/01.CIR.78.3.557.
- 71. Meier B, Gruentzig AR, Hollman J, et al. Does length or eccentricity of coronary stenoses influence the outcome of transluminal dilatation? *Circulation*. 1983;67:497–9. DOI: 10.1161/01.CIR.67.3.497.
- <span id="page-9-2"></span>72. Bredlau CE, Roubin GS, Leimgruber PP, et al. In-hospital morbidity and mortality in patients undergoing elective coronary angioplasty. *Circulation*. 1985;72:1044–52. DOI: 10.1161/01.cir.72.5.1044.
- <span id="page-9-3"></span>73. Redd DC, Roubin GS, Leimgruber PP, et al. The transstenotic pressure gradient trend as a predictor of acute complications after percutaneous transluminal coronary angioplasty. *Circulation*. 1987;76:792–801. DOI: 10.1161/01.cir.76.4.792.
- <span id="page-9-6"></span>74. Zapolanski A, Rosenblum J, Myler RK, et al. Emergency coronary artery bypass surgery following failed balloon angioplasty: Role of the internal mammary artery graft. *J Card Surg*. 1991;6:439–48. DOI: 10.1111/j.1540-8191.1991.tb00343.x.
- <span id="page-9-7"></span>75. Hollman J, Gruentzig AR, Douglas JS, et al. Acute occlusion after percutaneous transluminal coronary angioplasty--a new approach. *Circulation*. 1983;68:725–32. DOI: 10.1161/01. CIR.68.4.725.
- <span id="page-9-8"></span>76. Murphy DA, Craver JM, Jones EL, et al. Surgical revascularization following unsuccessful percutaneous transluminal coronary angioplasty. *J Thorac Cardiovasc Surg*. 1982;84:342–8. DOI: 10.1016/S0022-5223(19)39001-4.
- <span id="page-9-9"></span>77. Erbel R, Clas W, Busch U, et al. New balloon catheter for prolonged percutaneous transluminal coronary angioplasty and bypass flow in occluded vessels. *Cathet Cardiovasc Diagn*. 1986;12:116–23. DOI: 10.1002/ccd.1810120211.
- 78. Ferguson TB Jr, Hinohara T, Simpson J, et al. Catheter reperfusion to allow optimal coronary bypass grafting following failed transluminal coronary angioplasty. *Ann Thorac Surg*. 1986;42:399–405. DOI: 10.1016/s0003-4975(10)60545-0.
- <span id="page-9-10"></span>79. Marquis JF, Schwartz L, Aldridge H, et al. Acute coronary artery occlusion during percutaneous transluminal coronary angioplasty treated by redilation of the occluded segment. *J Am Coll Cardiol*. 1984;4:1268–71. DOI: 10.1016/s0735- 1097(84)80148-5.
- 80. Ellis SG, Roubin GS, King SB 3rd, et al. Angiographic and clinical predictors of acute closure after native vessel coronary

angioplasty. *Circulation*. 1988;77:372–9. DOI: 10.1161/01. CIR.77.2.372.

- 81. Simpfendorfer C, Belardi J, Bellamy G, et al. Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1987;59:267–9. DOI: 10.1016/0002- 9149(87)90797-1.
- 82. de Feyter PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up. *Circulation*.
- <span id="page-9-11"></span>1991;83:927–36. DOI: 10.1161/01.CIR.83.3.927. 83. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile. *J Am Coll Cardiol*. 1992;19:926–35. DOI: 10.1016/0735-1097(92)90272-o.
- <span id="page-9-12"></span>84. Turi ZG, Campbell CA, Gottimukkala MV, Kloner RA. Preservation of distal coronary perfusion during prolonged<br>balloon inflation with an autoperfusion angioplasty catheter.<br>*Circulation.* 1987;75:1273–80. DOI: 10.1161/01.cir.75.6.1273.
- <span id="page-9-13"></span>85. Van Lierde JM, Glazier JJ, Stammen FJ, et al. Use of an autoperfusion catheter in the treatment of acute refractory vessel closure after coronary balloon angioplasty: Immedi and six month follow up results. *Br Heart J*. 1992;68:51–4. DOI: 10.1136/hrt.68.7.51.
- <span id="page-9-14"></span>86. Leitschuh ML, Mills RM, Jacobs AK, et al. Outcome after major dissection during coronary angioplasty using the perfusion balloon catheter. *Am J Cardiol*. 1991;67:1056–60. DOI: 10.1016/0002-9149(91)90865-i.
- 87. Leitschuh ML, LaRosa D, Currier JW, et al. The "stack perfusion catheter" improves outcome following dissection during coronary angioplasty. *J Am Coll Cardiol*. 1990;15:A250. DOI: 10.1016/0735-1097(90)92715-E.
- 88. Landau C, Jacobs AK, Currier JW, et al. Long-term clinical follow-up of patients successfully treated with a perfusion balloon catheter for coronary angioplasty-induced dissections or abrupt closure. *Am J Cardiol*. 1994;74:733–5. DOI: 10.1016/0002-9149(94)90321-2.
- Saenz CB, Schwartz KM, Slysh SJ, et al. Experience with the use of coronary autoperfusion catheter during complicated angioplasty. *Cathet Cardiovasc Diagn*. 1990;20:276–8. DOI: 10.1002/ccd.1810200414.
- 90. Jackman JD, Zidar JP, Tcheng JE, et al. Outcome after prolonged balloon inflations of greater than 20 minutes for initially unsuccessful percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1992;69:1417–21. DOI:
- <span id="page-9-15"></span>10.1016/0002-9149(92)90893-4. 91. Teleflex. Teleflex expands interventional cardiology portfolio with FDA 510(k) clearance of the RingerTM perfusion balloon catheter. 2024. Available at: [https://investors.teleflex.com/](https://investors.teleflex.com/news/news-details/2024/Teleflex-Expands-Interventional-Cardiology-Portfolio-with-FDA-510k-Clearance-of-the-Ringer-Perfusion-Balloon-Catheter/default.aspx) [news/news-details/2024/Teleflex-Expands-Interventional-](https://investors.teleflex.com/news/news-details/2024/Teleflex-Expands-Interventional-Cardiology-Portfolio-with-FDA-510k-Clearance-of-the-Ringer-Perfusion-Balloon-Catheter/default.aspx)[Cardiology-Portfolio-with-FDA-510k-Clearance-of-the-Ringer-](https://investors.teleflex.com/news/news-details/2024/Teleflex-Expands-Interventional-Cardiology-Portfolio-with-FDA-510k-Clearance-of-the-Ringer-Perfusion-Balloon-Catheter/default.aspx)[Perfusion-Balloon-Catheter/default.aspx](https://investors.teleflex.com/news/news-details/2024/Teleflex-Expands-Interventional-Cardiology-Portfolio-with-FDA-510k-Clearance-of-the-Ringer-Perfusion-Balloon-Catheter/default.aspx) (accessed: 25 November 2024).
- <span id="page-9-16"></span>92. ClinicalTrials.gov. Investigation of the Ringer Perfusion Balloon Catheter (Ringer PTCA). ClinicalTrials.gov identifier: NCT04862689.. Available at: [www.clinicaltrials.gov/study/](https://www.clinicaltrials.gov/study/NCT04862689) [NCT04862689](https://www.clinicaltrials.gov/study/NCT04862689) (accessed: 25 November 2024).
- <span id="page-9-17"></span>93. Cardiovascular News. Ringer Perfusion Balloon Catheter Gains US FDA Approval. 2024. Available at: [https://](https://cardiovascularnews.com/ringer-perfusion-balloon-catheter-fda-approval/) [cardiovascularnews.com/ringer-perfusion-balloon-catheter-](https://cardiovascularnews.com/ringer-perfusion-balloon-catheter-fda-approval/)[fda-approval/](https://cardiovascularnews.com/ringer-perfusion-balloon-catheter-fda-approval/) (accessed: 1 August 2024).
- 94. U.S. Food & Drug Administration. 510(k) Premarket Notification. Available at: [www.accessdata.fda.gov/scripts/cdrh/cfdocs/](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233729)
- <span id="page-9-18"></span>[cfPMN/pmn.cfm?ID=K233729](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233729) (accessed: 11 December 2024). 95. Banka VS, Kochar GS, Maniet AR, Voci G. Progressive coronary dilation: An angioplasty technique that creates controlled<br>arterial injury and reduces complications. Am Heart J.<br>1993;125:61–71. DOI: 10.1016/0002-8703(93)90057-g.<br>96. Lee TC, Hartzler GO, Rutherford BD, McConahay DR.
- <span id="page-9-19"></span>Removal of an occlusive coronary dissection flap by using an atherectomy catheter. *Cathet Cardiovasc Diagn*. 1990;20:185–8. DOI: 10.1002/ccd.1810200307. 97. Smucker ML, Sarnat WS, Kil D, et al. Salvage from cardiogenic
- shock by atherectomy after failed emergency coronary artery angioplasty. *Cathet Cardiovasc Diagn*. 1990;21:23–5. DOI:
- 10.1002/ccd.1810210108. 98. Warner M, Chami Y, Johnson D, Cowley MJ. Directional coronary atherectomy for failed angioplasty due to occlusive coronary dissection. *Cathet Cardiovasc Diagn*. 1991;24:28–31.
- DOI: 10.1002/ccd.1810240107. 99. McKeever LS, Marek JC, Kerwin PM, et al. Bail-out directional atherectomy for abrupt coronary artery occlusion following conventional angioplasty. *Cathet Cardiovasc Diagn*. 1993;Suppl 1:31–6.
- <span id="page-9-20"></span>100. Reis GJ, Pomerantz RM, Jenkins RD, et al. Laser balloon angioplasty: Clinical, angiographic and histologic results. *J Am Coll Cardiol*. 1991;18:193–202. DOI: 10.1016/s0735- 1097(10)80240-2.
- 101. Spears JR, Reyes VP, Wynne J, et al. Percutaneous coronary laser balloon angioplasty: Initial results of a multicenter experience. *J Am Coll Cardiol*. 1990;16:293–303. DOI: 10.1016/0735-1097(90)90576-b.
- 102. Saito S, Arai H, Kim K, Aoki N. Initial clinical experiences with rescue unipolar radiofrequency thermal balloon angioplasty

after abrupt or threatened vessel closure complicating elective conventional balloon coronary angioplasty. *J Am Coll Cardiol*. 1994;24:1220–8. DOI: 10.1016/0735-1097(94)90102-3.

- 103. Fram DB, McKay RG. 'Hot' balloon angioplasty: radiofrequency,<br>neodymium: yag, and microwave. In: Topol EJ, (ed). Textbook of Interventional Cardiology. 2nd ed. Philadelphia: WB Saunders, 1994;239–240.
- Nardone D, Bravette B, Shi Y, et al. Effect of microwave thermal angioplasty on intracoronary thrombus. *Circulation*. 1991;84(Suppl.2):II300.
- <span id="page-9-21"></span>105. Sigwart U, Urban P, Golf S, et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. *Circulation*. 1988;78:1121–7. DOI: 10.1161/01.cir.78.5.1121.
- <span id="page-9-22"></span>106. Fischman DL, Savage MP, Leon MB, et al. Effect of intracoronary stenting on intimal dissection after balloon angioplasty: Results of quantitative and qualitative coronary analysis. *J Am Coll Cardiol*. 1991;18:1445–51. DOI: 10.1016/0735-1097(91)90673-w.
- 107. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. *Circulation*.
- 1992;85:916–27. DOI: 10.1161/01.cir.85.3.916. 108. Vrolix M, Piessens J. Usefulness of the Wiktor stent for treatment of threatened or acute closure complicating coronary angioplasty. The European Wiktor Stent Study Group. *Am J Cardiol*. 1994;73:737–41. DOI: 10.1016/0002- 9149(94)90873-7.
- <span id="page-9-23"></span>109. Herrmann HC, Buchbinder M, Clemen MW, et al. Emergent use of balloon-expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. *Circulation*. 1992;86:812–9. DOI: 10.1161/01.CIR.86.3.812.
- 110. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. *N Engl J*
- *Med.* 1994;331:489–95. DOI: 10.1056/NEJM199408253310801.<br>111. Colombo A, Goldberg SL, Almagor Y, et al. A novel strategy<br>for stent deployment in the treatment of acute or threatened closure complicating ballon coronary angioplasty: Use of short or standard (or both) single or multiple Palmaz-Schatz stents. *J Am Coll Cardiol*. 1993;22:1887–91. DOI: 10.1016/0735- 1097(93)90774-U.
- <span id="page-9-24"></span>112. de Muinck ED, den Heijer P, van Dijk RB, et al. Autoperfusion balloon versus stent for acute or threatened closure during percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1994;74:1002–5. DOI: 10.1016/0002-9149(94)90848-6.
- 113. de Muinck ED, den Heijer P, Peels H-O, et al. 720-5 Perfusion balloon versus stent for acute or threatened closure: Equal efficacy but higher mortality and costs after stenting. *J Am Coll Cardiol*. 1995;25:123A. DOI: 10.1016/0735-1097(95)91966- 2.
- 114. Pragliola C, Kootstra GJ, Lanzillo G, et al. Current results of coronary bypass surgery after failed angioplasty. *J Cardiovasc*
- <span id="page-9-25"></span>*Surg (Torino)*. 1994;35:365–9. 115. Emanuelsson H, Serruys PW, Belardi J, et al. 741-1 Clinical experience with heparin-coated stents – The Benestent II Pilot Phase 1. *J Am Coll Cardiol*. 1995;25:181A. DOI: 10.1016/0735-
- 1097(95)92212-N. 116. Mahadevan K, Cosgrove C, Strange JW. Factors influencing stent failure in chronic total occlusion coronary intervention. *Interv Cardiol*. 2021;16:e27. DOI: 10.15420/icr.2021.03.
- <span id="page-9-26"></span>117. Kleber FX, Mathey D, Rittger H, Scheller B. How to use the drug-eluting balloon: Recommendations by the German consensus group. *EuroIntervention*. 2011;7:K125–8. DOI: 10.4244/EIJV7SKA21.
- 118. Rosenberg M, Waliszewski M, Chin K, et al. Prospective, largescale multicenter trial for the use of drug-coated balloons in coronary lesions: The DCB-only All-comers Registry. *Catheter*
- *Cardiovasc Interv*. 2019;93:181–8. DOI: 10.1002/ccd.27724. 119. Uskela S, Kärkkäinen JM, Eränen J, et al. Percutaneous coronary intervention with drug‐coated balloon‐only strategy in stable coronary artery disease and in acute<br>coronary syndromes: An All-comers Registry Study.<br>*Catheter Cardiovasc Interv.* 2019;93:893–900. DOI: 10.1002/ ccd.27950.
- 120. Scheller B, Ohlow M-A, Ewen S, et al. Bare metal or drugeluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: The randomised PEPCAD NSTEMI trial. *EuroIntervention*. 2020;15:1527–33. DOI: 10.4244/ EIJ-D-19-00723.
- 121. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: The BELLO (Balloon Elution and Late Loss Optimization) study. *J Am Coll Cardiol*. 2012;60:2473–80. DOI: 10.1016/j. jacc.2012.09.020.
- 122. Toelg R, Merkely B, Erglis A, et al. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: Clinical results of the international real-world DELUX registry. *EuroIntervention*. 2014;10:591–9. DOI: 10.4244/EIJV10I5A102.
- 123. Cortese B, Silva Orrego P, Agostoni P, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. *JACC Cardiovasc Interv*. 2015;8:2003–9. DOI: 10.1016/j.jcin.2015.08.029.